TG ImmunoPharma Announces FDA Clearance for Clinical Trial of TGI-6 Bispecific Antibody

"We are thrilled to receive FDA clearance for the clinical trial of TGI-6," said Professor Zhigang Tian, founder of TGI and member of the Chinese Academy of Engineering and the Academia Europaea. "TGI-6 has demonstrated superior anti-tumor activity and safety in preclinical studies. We have great confidence in its potential as a novel therapy for solid tumors." "We are thrilled to receive FDA clearance for the clinical trial of TGI-6," said ProfessorZhigang Tian, founder of TGI and member of...

"We are thrilled to receive FDA clearance for the clinical trial of TGI-6," said Professor Zhigang Tian, founder of TGI and member of the Chinese Academy of Engineering and the Academia Europaea. "TGI-6 has demonstrated superior anti-tumor activity and safety in preclinical studies. We have great confidence in its potential as a novel therapy for solid tumors."

With this significant milestone, TGI is actively seeking global partners to collaborate on the development, clinical trials, and eventual commercialization of TGI-6. By partnering with pharmaceutical and biotechnology companies, TGI aims to leverage their expertise in clinical development and market access, expediting the availability of TGI-6 for patients worldwide.

TGI remains steadfast in its mission to revolutionize cancer treatment through innovative immunotherapies. With FDA clearance for the clinical trial of TGI-6, the company is poised to advance the development of precise therapies for solid tumors. Interested parties are invited to explore partnership opportunities and join TGI in their pursuit of delivering novel treatment options that improve patient outcomes.

About TG ImmunoPharma Co., Ltd. (TGI)

TG ImmunoPharma Co., Ltd. (TGI) is a leading biotech company dedicated to the development of novel immunotherapeutic drugs. Focusing on innovation and research, TGI harnesses the power of the immune system to combat cancer and enhance patient outcomes. The company's diverse pipeline includes bispecific antibodies, immune checkpoint inhibitors, NK/T-cell engagers, and immunocytokines. TGI has successfully developed over 10 pipeline products, with more than half having completed pre-clinical studies. Notably, TGI-2, an anti-PVRIG therapeutic antibody, has initiated Phase 1 trials in the United States and is nearing completion of its first patient dosing. TGI envisions three innovative drugs entering Phase I trials by the end of next year, demonstrating its commitment to advancing immunotherapy and addressing unmet needs in cancer treatment worldwide. To learn more about TGI and its pipeline, please visit www.tgimmunopharma.com.

For further information or partnership inquiries, please contact:

Dr. SUN Haoyu,
Head of Operation, TG ImmunoPharma
haoyu.sun@tgimmunopharma.com

View original content:https://www.prnewswire.co.uk/news-releases/tg-immunopharma-announces-fda-clearance-for-clinical-trial-of-tgi-6-bispecific-antibody-301853097.html